Dasatinib for the treatment of acute lymphoblastic leukaemia
Status Discontinued
Decision Selected
Process STA pre-2018
Referral date 01 June 2008
Topic area
  • Cancer

The above topic was referred to NICE as part of the 17th wave referrals and you were invited to participate in this single technology appraisal in July 2008. Following a detailed review of the number of patients anticipated to be treated by dasatinib for acute lymphoblastic leukaemia, we have concluded that further discussions with the Department of Health are required to establish how best to progress this appraisal.

We are therefore suspending this single technology appraisal whilst we consider the next steps.

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
23 December 2008 Please note that this topic has been removed from the technology appraisals work programme.

For further information on our processes and methods, please see our CHTE processes and methods manual